{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:24:37Z","timestamp":1777577077510,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"FDA\/CBER Intramural"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.vaccine.2016.11.044","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T22:58:40Z","timestamp":1481842720000},"page":"694-702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines"],"prefix":"10.1016","volume":"35","author":[{"given":"Sandra","family":"Fuentes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Arenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Golding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surender","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.11.044_b0005","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2016.11.044_b0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2007.01578.x","article-title":"Safety procedures of coagulation factors","volume":"13","author":"Jorquera","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.vaccine.2016.11.044_b0015","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1128\/JVI.01853-08","article-title":"A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction","volume":"83","author":"Moore","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.044_b0020","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1128\/JVI.73.9.7099-7107.1999","article-title":"Respiratory syncytial virus G and\/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB\/c mice","volume":"73","author":"Tripp","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.044_b0025","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1128\/JVI.01296-09","article-title":"Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice","volume":"83","author":"Zaitseva","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.044_b0030","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1128\/JVI.03426-12","article-title":"Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells","volume":"87","author":"Zaitseva","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.044_b0035","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1128\/JVI.03340-14","article-title":"Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus","volume":"89","author":"Zaitseva","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.044_b0040","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.11.044_b0045","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1128\/AAC.48.5.1811-1822.2004","article-title":"Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model","volume":"48","author":"Mejias","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2016.11.044_b0050","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.inf.0000133165.85909.08","article-title":"Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection","volume":"23","author":"Saez-Llorens","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.11.044_b0055","doi-asserted-by":"crossref","first-page":"8193","DOI":"10.1128\/JVI.00133-15","article-title":"Nonglycosylated G-protein vaccine protects against homologous and heterologous respiratory syncytial virus (RSV) challenge, while glycosylated G enhances RSV lung pathology and cytokine levels","volume":"89","author":"Fuentes","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.044_b0060","doi-asserted-by":"crossref","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2016.11.044_b0065","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2016.11.044_b0070","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1128\/AAC.49.11.4700-4707.2005","article-title":"Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency","volume":"49","author":"Mejias","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2016.11.044_b0075","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1016\/j.vaccine.2013.05.088","article-title":"Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection","volume":"31","author":"Fuentes","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.11.044_b0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1743-422X-10-195","article-title":"A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment","volume":"10","author":"Varada","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2016.11.044_b0085","doi-asserted-by":"crossref","first-page":"9147","DOI":"10.1128\/JVI.00121-11","article-title":"Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs","volume":"85","author":"Zaitseva","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.044_b0090","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1038\/ncomms6104","article-title":"Visualizing the replication of respiratory syncytial virus in cells and in living mice","volume":"5","author":"Rameix-Welti","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2016.11.044_b0095","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1128\/JVI.00338-16","article-title":"Influence of respiratory syncytial virus F glycoprotein conformation on induction of protective immune responses","volume":"90","author":"Palomo","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.11.044_b0100","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.11.044_b0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00006454-199802000-00006","article-title":"Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group","volume":"17","author":"Subramanian","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.11.044_b0110","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00006454-199809000-00007","article-title":"Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group","volume":"17","author":"Saez-Llorens","year":"1998","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16311057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16311057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:50:39Z","timestamp":1601254239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16311057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0264410X16311057"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}